January 23, 2012 | Cell Therapy, Commercialization

Bench To Bedside: Cell Therapy Development and Commercialization Roadmap

PCT's Dr. Sanjin Zvonic, drawing on more than 12 years of PCT's philosophy, experience and expertise, gives an overview of the key steps in the commercialization of cell therapy products, in the article published in BioProcess International Yearbook 2011-2012.

Please follow the link to read and download the full article: http://www.bioprocessintl.com/journal/2011/August/Bench-to-Bedside-320070
*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH are all now operating under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.

Stay up to date on the latest cell therapy industry insights

Related Articles

April 25, 2017

Planning Ahead: Selecting Appropriate Source Materials for Cell-Based Therapy Manufacturing

Cell-based therapies are rapidly changing the way the medical industry is treating a wide range of diseases. As the development of these therapies continues to advance, effective planning ...

Read More
March 14, 2016

Accelerating Our Vision of Global Commercial Cell Therapy Manufacturing

In November 2014, Japan passed a new regenerative medicine law, the upshot of which is that it enables therapeutic development sponsors to receive conditional marketing approval and ...

Read More
April 27, 2016

Patient-Specific Cell Therapies: Not your Grandfather’s Therapies

The following is an excerpt from an article published in the April issue of BioProcess international, entitled “Factories of the Future: Can Patient-Specific Cell Therapies Get there from ...

Read More

Subscribe to Our Email Distribution List
© 2024 Minaris Regenerative Medicine   |  Privacy Policy   |  Imprint